BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 885 filers reported holding BAXTER INTL INC in Q3 2023. The put-call ratio across all filers is 0.40 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $7,670,000 | +104.5% | 99,500 | +95.9% | 0.06% | +144.0% |
| Q2 2018 | $3,751,000 | -39.7% | 50,794 | -46.9% | 0.02% | -41.9% |
| Q1 2018 | $6,218,000 | +191.8% | 95,600 | +190.0% | 0.04% | +152.9% |
| Q4 2017 | $2,131,000 | -63.5% | 32,967 | -64.6% | 0.02% | -54.1% |
| Q3 2017 | $5,841,000 | -24.4% | 93,078 | -27.1% | 0.04% | -24.5% |
| Q2 2017 | $7,731,000 | +64.7% | 127,700 | +41.1% | 0.05% | +28.9% |
| Q1 2017 | $4,693,000 | -73.8% | 90,487 | -77.6% | 0.04% | -78.0% |
| Q4 2016 | $17,893,000 | -14.3% | 403,540 | -8.0% | 0.17% | -8.5% |
| Q3 2016 | $20,868,000 | -25.9% | 438,400 | -29.6% | 0.19% | -8.7% |
| Q2 2016 | $28,145,000 | -3.5% | 622,406 | -12.3% | 0.21% | -26.6% |
| Q1 2016 | $29,154,000 | +138.3% | 709,700 | +121.3% | 0.28% | +151.8% |
| Q4 2015 | $12,235,000 | -49.0% | 320,700 | -8.4% | 0.11% | -50.2% |
| Q1 2015 | $23,975,000 | -6.5% | 350,000 | 0.0% | 0.22% | -28.6% |
| Q4 2014 | $25,652,000 | +11053.0% | 350,000 | +10837.5% | 0.32% | +7775.0% |
| Q3 2014 | $230,000 | -83.5% | 3,200 | -84.9% | 0.00% | -80.0% |
| Q3 2013 | $1,393,000 | – | 21,200 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 200,000 | $7,548,000 | 6.60% |
| BOONE CAPITAL MANAGEMENT LLC | 469,405 | $17,715,345 | 5.59% |
| Soditic Asset Management LLP | 186,920 | $7,054,361 | 5.43% |
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 131,000 | $4,943,940 | 4.32% |
| Camber Capital Management LP | 3,000,000 | $113,220 | 3.73% |
| Carmignac Gestion | 4,848,773 | $182,991,718 | 3.36% |
| SHAPIRO CAPITAL MANAGEMENT LLC | 3,028,799 | $114,306,874 | 3.33% |
| Hillman Capital Management, Inc. | 219,248 | $8,274,420 | 3.19% |
| Cincinnati Specialty Underwriters Insurance CO | 201,500 | $7,604,610 | 2.90% |
| Callodine Capital Management, LP | 265,000 | $10,001,100 | 2.79% |